Can memantine prevent memory impairment induced by MDMA in humans.

This double-blind, placebo-controlled crossover trial (n=16) investigates whether pretreatment with memantine can prevent the memory impairment typically caused by MDMA in recreational users.

Led by Maastricht University, the study aims to assess memory performance using verbal and prospective memory tests, with event-related potentials measured during the verbal memory task.

Memantine, a drug used in Alzheimer’s treatment, will be administered two hours before MDMA or placebo. The study, employing a 4-way crossover design, anticipates enrolment to begin in April 2011 and seems to have been completed (but the study record not updated).

You can find the results of the study here.

Trial Details

This double-blind trial (n=16) led by Maastricht University aims to determine if memantine can prevent MDMA-induced memory impairment in recreational users. Participants will receive memantine or placebo before MDMA, with memory performance assessed through verbal and prospective memory tests. The study, pending recruitment, adopts a 4-way crossover design, anticipating enrolment to start in April 2011.

NCT Number NL2664

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.